Editor in Chief PharmacoEconomics. Past President ISPOR NZ Chapter, ex pharmacist, run and play the piano. UK expat in New Zealand. All views are my own
New Zealand
Joined January 2010
- Tweets9.3K
- Following1.3K
- Followers2.3K
- Likes2.1K
PharmacoEconomics has a Call For Papers for a themed issue on individual level models link.springer.com/collection…
Chris Carswell retweeted
A much needed reporting checklist for discrete choice experiments link.springer.com/article/10…
Seems to me the QALY is so entrenched in many countries it would take a huge effort to move away from it
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Chris Carswell retweeted
Second, this solo editorial in Pharmacoeconomics, called "Making Models Fit for Purpose: the Importance of Ensuring Stakeholder Involvement". Also available free right here! rdcu.be/dwnP1
Chris Carswell retweeted
My 'Framework for the Fair Pricing of Medicines' has just been published as a Leading Article by Pharmacoeconomics. This framework proposes a number of advancements to existing approaches for specifying a 'cost-effectiveness threshold' for new medicines. link.springer.com/article/10…
Chris Carswell retweeted
Including carer outcomes in economic evaluation is important & can reveal unrecognised challenges in HTA decisions.
One of these is where patient & carer QALYs point in different directions - work led by @davidjohnmott and colleagues @OHENews @HEU_UoB
link.springer.com/article/10…
Chris Carswell retweeted
1/3 "Using Age-Specific Values for Pediatric HRQoL in CEA: Is There a Problem to Be Solved? If So, How?" available here👉 tinyurl.com/45xn56sk
Really pleased this paper is out - hope it serves to progress the debate! @stolk_elly @MJSculpher @rich_norman @QUOKKA_Research
Chris Carswell retweeted
Thread update on the QUOKKA project led by the brilliant @nancydevlin1 - huge output from this multi-university project on measuring and valuing child QoL
1/10 Time flies! @QUOKKA_Research is now in its 3rd and final year. Here's a thread with a quick overview of where we're at and what we'll be doing this year!
Chris Carswell retweeted
Congratulations @dinaabushanab10 on this massive work on projecting the health and economic burden of CVD among people with type 2 diabetes @claremarquina @JedidiahMorton @PECjournal link.springer.com/article/10…
Chris Carswell retweeted
In preparation for my new class @HarrisPolicy, I asked ChatGPT:
“How to conduct cost-effectiveness analysis (CEA)?”
ChatGPT provides a very solid high-level summary, and I don’t think I can do a better job.
Thoughts? @PeterNeumann11 @Basucally @AnkurFactorial @WrightCensored
Chris Carswell retweeted
At @ipha's conference. The Minister just mentioned Ireland's €45,000/QALY threshold and that there is an existing pathway for orphan drugs to exceed it. Interesting confirmation of the threshold and that it doesn't always apply.
Chris Carswell retweeted
@BCNHealth publishes a study reviewing economic evaluations and burden of disease studies of endometriosis
#health #review #economic #evaluation #burden #disease #endometriosis #costs #indirect #productivity #losses
bit.ly/3EBmAZT
Chris Carswell retweeted
Antimicrobial resistance or #AMR, as known in short, is a global health crisis.
Find out how we're applying a new 'Netflix' style payment model to boost the antimicrobial pipeline, which has already assessed 2 new antimicrobial drugs⬇️
link.springer.com/article/10…
Good news for pet owners pubmed.ncbi.nlm.nih.gov/3670… @joeymattingly
Chris Carswell retweeted
PharmacoEconomics has just published my invited & peer-reviewed Practical Application:
"Modelling the Cost-Effectiveness of Diagnostic Tests"
You can read the full text at rdcu.be/c32S7 (no subscription needed)
#HealthEcon #CostEffectiveness #HTA